• *
  Reductions in HbA1c and body weight.
• ¤
  In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.

References:

• 1.
  Local SMPC Empagliflozin (Summary of Product Characteristics). July 2023.
• 2.
  Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME® Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
• 3.
  Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. (SUSTAIN-6 results and the publication’s Supplementary Appendix.)